Natural ASA 1Q presentasjon 2001

Størrelse: px

Begynne med side:

Download "Natural ASA 1Q presentasjon 2001"

Espen Lindberg
8 år siden
Visninger:

1 Natural ASA 1Q presentasjon 2001 Hovedelementer 1Q 2001 Tonalin /CLA-salget Natural historiske kvartalstall Strategiske alternativer for Natural-konsernet 1

2 1Q 2001 Hovedelementer 1 Salgsøkning Tonalin /CLA på 72 % 1q,00 til 1q,01 Salgsøkning Tonalin /CLA på 317 % i USA/Canada 1q,00 til 1q,01 Norden/Europe på linje med siste kvartaler Bruttomargin på 59,5% q'00 4q'00 1q'01 2

USA/Canada 1q,00 til 1q,01 Norden/Europe på linje med siste

3 1Q 2001 Hovedelementer 2 F&U 6,5 mill. kr. i 1Q 2001 mot 4,1 mill. kr. 1Q 2000 BASF i rute, flere studier ferdig ; positive trender Pilotanlegget i drift i juni, kostnadsrammen på 11 mill kr. holder LEF-saken avsluttet med prinsipiell enighet om forlik Nye medarbeidere, Hogne Vik og Egil Nielsen 3

4 1Q 2001 Hovedelementer 3 Europa-satsingen forventet effekt 2q 4q,01 OTC Pharma International Introduksjon Nederland/Belgia i mai/juni og Østerike i q3,01 Syd Afrika planlegges q4,01 I Italia vurderes ny samarbeidspartner Skandinavia/Norden Flytende Tonalin /CLA-TG i butikkhyllene i mai i Norge Lansering gjennom Norgesgruppen, Hakon og COOP (CLAREN) USA/Canada fortsetter med bred pressedekning 4

vurderes ny samarbeidspartner Skandinavia/Norden Flytende Tonalin /CLA-TG i butikkhyllene i mai i

5 1Q 2001 Hovedelementer 4 Ny markedspakke godt mottatt hos våre kunder Midelfart investerer 6-8 mill. i A&P (Media og TV) Prosjekt igangsatt for å introdusere Tonalin /CLA i utvalgte land i Asia fra 2002/2003 5

6 Tonalin /CLA salg geografisk CLA-salg NO K Q Q Q 2000 Akk Norden Resten av Europa Nord-Amerika Resten av verden Sum CLA-salg

2000 Norden 6 884 11 073 5 276 34 589 Resten av Europa 2 158 1 083

7 Tonalin /CLA DS Sales Scandinavia/Nordic (1998) - 34 MNOK (2000) - Potential MNOK USA/Canada (1997) - 42 MNOK (2000) - Potential MNOK Europe/EU (2001/2002) - 3 MNOK (2000) - Potential 350+ MNOK - UK (P4H + 2nd dist.) - BeNeLux (May/June 2001) - Østerike (q3, 2001) - Frankrike - Italia - Hellas - Spania Asia (2002/2003) - 5 MNOK (2000) - Potential MNOK - P.R. China - Singapore - Malaysia - Indonesia - Thailand - Korea - Taiwan 7

dist.) - BeNeLux (May/June 2001) - Østerike (q3, 2001) - Frankrike - Italia - Hellas - Spania Asia (2002/2003) -

8 Business Idea Shaping People VISION Develop know-how and document nutrition technologies for high value functional ingredients to the food and feed industries MISSION Develop the business potential of CLA with maximum value for Natural 8

ingredients to the food and feed industries MISSION Develop

9 Industry-Market Overview Pharmaceutical industry Functional Foods $ billion Dietary Supplements $ 5-10 billion - Ethical $ billion - OTC - VMS + Herbal Medicinal Foods $ 1-2 billion Food industry Cosmetics/Toiletry Technology for $ 45 billion Biofunctional Lipids - Skin care/colour Ingredients - Fragrancies Producers $ billion - VMS - Specialities (Oils) $ billion - Food - Beverages Animal Feed industry $ billion - Ingredients 9

Cosmetics/Toiletry Technology for $ 45 billion Biofunctional Lipids - Skin care/colour Ingredients - Fragrancies

10 CLA Market Development Phase The potential of a Vitamin! Development Growth Mature Markets being defined and created. Markets being grown and developed. Markets being managed and maintained. Vit. & Min. Fiber & Proteins Probiotics Omega-3/GLA Antioxidants Prebiotics CLA Phytochemicals 10

Markets being grown and developed. Markets being managed and maintained.

11 CLA Commercial Potential Develop the business potential of CLA with maximum value for Natural Business Area NTR Potential Annual Income (MNOK) CLA in Dietary Supplements (Body Comp.) CLA in Animal Feed (BASF) CLA in Food CLA in Cosmetics CLA in Pharma Success with Tonalin /CLA in DS, Feed, Food, (and Cosmetics and Pharma) is a requirement for Natural to prove capability in commercialising ingredient technologies. 11

000 CLA in Animal Feed (BASF) 300-400 CLA in Food 200-500 CLA in Cosmetics 50-100 CLA in Pharma 100-200 Success

12 Natural Strategic Position BIOTECH Crop/Feed Grown Feed Universities, Research Institutes & Organizations, Foundations, and Others Natural - IPR - Development BIOTECH Medicine Ingredient Supplier(s) - Commercialization Ingredient Supplier(s) Pharmaceutical Feed Manufacturer Food Manufacturer Animal Feed Functional Foods Dietary supplements and OTC PATENTS REGULATORY MARKET POSITION 12

Supplier(s) - Commercialization Ingredient Supplier(s) Pharmaceutical Feed Manufacturer Food

13 CLA from DS to Industry Test Market ; Dietary Supplements Strong CLA sales growth globally 100 s of tons Multi-National 1 consumer market segment Industrial market; CLA in Food/OTC(/Pharma&Cosmetics) Significant players evaluating opportunity Industrial capability ( s tons vs. 100 s tons) Regulatory management Distribution power (global/industrial coverage needed) B2B M&S power 13

Food/OTC(/Pharma&Cosmetics) Significant players evaluating opportunity Industrial capability (10.

14 Managing external factors Legal Competing Products Regulatory Suppliers and Providers IPR (Patent & Trademark) Natural ASA - CLA Technology - CLA IPR - CLA Sales in DS - CLA License BASF Competing Companies Global Food and Pharma companies Feed DS Food Commoditisation 14

Technology - CLA IPR - CLA Sales in DS - CLA License BASF Competing

15 Avoid commoditization Few players Protection? Many players No protection * No willingness to invest * War on margins/costs * Patents without value 15

16 Requirements for Success in CLA Strong IPR and Technology protection Patent/License portfolio and Know-How Trademark(s) Developed market awareness (Business opportunity) Proof of Concept (PoC) Sales/(Potential) documented (and growing) Global industrial partner(s) invest in CLA 16

awareness (Business opportunity) Proof of Concept (PoC)

17 Industry players in Food & OTC Ingredient suppliers Integrators Food companies DESHEA Food comp. Pharma - OTC Roche Bayer BASF Loders Crok. Denofa Cargil Monsanto Unilever ConAgra Nestlè Danone Coca Cola Kraft Hershey National Medium/Small Already customers P&G Abbot Sanofi Nycomed Supply all Product-Market segments Products in market segments Diet, energy and snack products OTC and VMS, Moving in to Energy/Health sector 17

Denofa Cargil Monsanto Unilever ConAgra Nestlè Danone Coca Cola Kraft Hershey National Medium/Small

18 Natural/CLA growth opportunities ALTERNATIVE STRENGTH WEAKNESS Production Flexibility Complex alliance NTR controls Management Strategic Power mngmnt Dep. on partner(s) JV/Alliance Combined cap. Alone Control (?) Capacity Competence 18

controls Management Strategic Power mngmnt Dep.

19 CLA is Natural and Essential CLA is a natural essential fatty acid The human body needs it CLA is patented CLA has a wide range of application areas Natural has a unique protected position (IPR) Can substitute fat in all feed and food 19

a wide range of application areas Natural has a unique

20 Vedlegg 20

21 The TimeLine for CLA Shaping People Develop the business potential of CLA with maximum value for Natural DS Income CLA discovered CLA Commercialised in DS CLA Industrialised in Feed CLA Industrialised in Food Food Royalty Income Feed Royalty Income CLA Industrialised in Cosmetics CLA Industrialised in Pharma 21

22 Natural kvartalstall 1. kv kv kv kv kv. 00 Driftsinntekter Driftsresultat Netto Finans Ordinært resultat før skattekost Periodens resultat Res. pr aksje av periodens resultat -0,12-1,03-0,55-0,27 0,10 22

Like dokumenter

Natural ASA 3Q presentasjon 2001

Natural ASA 3Q presentasjon 2001 Agenda: Nyhet! Resultat 3Q CLA et vitamin med stort potensiale 1 Kvartalspresent asjon BASF dyrefôr BASF bekrefter beslutning om å introdusere CLA i dyrefôr. Gris er først;